Takeda Pharmaceutical Company Limited vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Pharma Giants' Gross Profit Showdown: Takeda vs. Supernus

__timestampSupernus Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20141162870001256834000000
Thursday, January 1, 20151360040001271973000000
Friday, January 1, 20162030170001173296000000
Sunday, January 1, 20172870230001274610000000
Monday, January 1, 20183935410001437534000000
Tuesday, January 1, 20193760950002201424000000
Wednesday, January 1, 20204679380002203504000000
Friday, January 1, 20215047140002462160000000
Saturday, January 1, 20225800170002783406000000
Sunday, January 1, 20235237420002832257000000
Monday, January 1, 20242832257000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Pharmaceutical Giants: Gross Profit Analysis

In the competitive world of pharmaceuticals, financial performance is a key indicator of success. This analysis compares the gross profit trends of Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Takeda, a global leader, consistently outperformed Supernus, with gross profits peaking at approximately 2.83 trillion in 2023, marking a 125% increase from 2014. In contrast, Supernus, a smaller player, showed impressive growth, with gross profits rising by nearly 350% over the same period, reaching around 580 million in 2022. However, 2023 saw a slight dip to 524 million. This data highlights Takeda's dominance in scale, while Supernus showcases remarkable growth potential. The absence of data for Supernus in 2024 suggests a need for further investigation. This financial narrative underscores the dynamic nature of the pharmaceutical industry, where both giants and emerging players shape the landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025